复发/难治性大B细胞淋巴瘤患者接受嵌合抗原受体T细胞治疗后发生急性肾损伤与较差生存相关
该研究评估了155例接受CAR-T治疗的复发/难治性大B细胞淋巴瘤患者中急性肾损伤(AKI)的发生率和危险因素。28例(18%)发生AKI,中位达峰肌酐时间为9.5天。多变量分析显示慢性肾病病史(aRR 3.5)和接受阿基仑赛(aRR 2.1)与AKI独立相关。发生AKI的患者中位无进展生存期(2.4 vs 6.9个月)和总生存期(7.8 vs 29.7个月)更短。
要点
- 155例CAR-T治疗患者中28例(18%)发生AKI,中位达峰肌酐时间9.5天。
- 慢性肾病病史(aRR 3.5,95%CI 1.9-6.4)和接受阿基仑赛(aRR 2.1,95%CI 1.1-4.0)与AKI独立相关。
- 发生AKI患者的中位PFS(2.4 vs 6.9个月,p=0.02)和OS(7.8 vs 29.7个月,p<0.01)更短。
核心结论
- CAR-T治疗后发生AKI与复发/难治性大B细胞淋巴瘤患者较差的PFS和OS相关。
- 需要进一步研究以预防肾毒性并改善CAR-T治疗后的结局。
研究设计与样本
- 研究纳入155例接受CAR-T治疗的复发/难治性大B细胞淋巴瘤患者,评估AKI的发生率和危险因素。
主要发现
- 155例患者中28例(18%)发生AKI,中位达峰肌酐时间为9.5天(范围3-30天)。
- AKI病因包括容量不足(n=20,71%)、细胞因子释放综合征(n=5,18%)、肾毒性药物(n=5,18%)、肿瘤溶解综合征(n=1,4%)和多因素(n=6,21%)。
- 单变量分析中,慢性肾病病史(RR 3.5,95%CI 1.9-6.6,p<0.01)、接受阿基仑赛(RR 2.1,95%CI 1.1-4.2,p=0.04)、铁蛋白升高(RR 3.1,95%CI 1.1-8.4,p=0.03)和血清肌酐水平(RR 2.9,95%CI 1.4-6.2,p<0.01)与AKI相关。
- 多变量分析中,慢性肾病病史(aRR 3.5,95%CI 1.9-6.4,p<0.01)和接受阿基仑赛(aRR 2.1,95%CI 1.1-4.0,p=0.03)保留统计学显著性。
- 4例(2.6%)患者在CAR-T期间需要肾脏替代治疗;28例AKI患者中25例肾功能恢复,中位恢复时间14天(范围5-85天);未恢复者中2例需要长期血液透析,1例疾病进展并在CAR-T后34天死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T-cell (CAR-T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CAR-T for relapsed/refractory large B-cell lymphoma. Among 155 patients, 28 (18%) developed AKI with a median time-to-peak creatinine from CAR-T of 9.5 days (range = 3-30). Aetiologies included volume depletion (n = 20, 71%), cytokine release syndrome (n = 5, 18%), nephrotoxins (n = 5, 18%), tumour lysis syndrome (n = 1, 4%) and multifactorial (n = 6, 21%). On univariable analysis, a history of chronic kidney disease (CKD) relative risk (RR 3.5, 95% CI: 1.9-6.6, p < 0.01), receipt of axicabtagene ciloleucel (RR 2.1, 95% CI: 1.1-4.2, p = 0.04), elevated ferritin (RR 3.1, 95% CI: 1.1-8.4, p = 0.03) and serum creatinine level (RR 2.9, 95% CI: 1.4-6.2, p < 0.01) were associated with AKI. On multivariable analysis, a history of CKD adjusted relative risk (aRR 3.5, 95% CI: 1.9-6.4, p < 0.01) and receipt of axicabtagene ciloleucel (aRR 2.1, 95% CI: 1.1-4.0, p = 0.03) retained statistical significance. Four (2.6%) patients required renal replacement therapy during CAR-T. Twenty-five of 28 patients with AKI had renal recovery with a median time to recovery of 14 days (range = 5-85). Of those without renal recovery, two required long-term haemodialysis and one experienced disease progression and died 34 days after CAR-T. Patients with AKI had shorter median PFS (2.4 vs. 6.9 months, p = 0.02) and OS (7.8 vs. 29.7 months, p < 0.01). Additional research is needed to obviate the risk of renal toxicity and improve post-CAR-T outcomes.
引用
- Sharp J, Zhao Q, Voorhees TJ, et al. Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma. Br J Haematol. 2025. PMID: 40589093. doi:10.1111/bjh.20240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。